Medulloblastoma (MB), the most common malignant paediatric brain tumor, is currently treated using a combination of surgery, craniospinal radiotherapy and chemotherapy. Owing to MB stem cells (MBSCs), a subset of MB patients remains untreatable despite standard therapy. CD133 is used to identify MBSCs although its functional role in tumorigenesis has yet to be determined. In this work, we showed enrichment of CD133 in Group 3 MB is associated with increased rate of metastasis and poor clinical outcome. The signal transducers and activators of transcription-3 (STAT3) pathway are selectively activated in CD133 + MBSCs and promote tumorigenesis through regulation of c-MYC, a key genetic driver of Group 3 MB. We screened compound libraries for STAT3 inhibitors and treatment with the selected STAT3 inhibitors resulted in tumor size reduction in vivo. We propose that inhibition of STAT3 signaling in MBSCs may represent a potential therapeutic strategy to treat patients with recurrent MB.
INTRODUCTION
Brain tumors represent the leading cause of childhood cancer mortality, of which medulloblastoma (MB) is the most common malignant pediatric brain tumor. MB most often arises in the cerebellum of infants and young children, and was originally described as a primitive neuroectodermal tumor. 1, 2 Although tremendous improvements in therapy regimens using a combination of surgical resection, craniospinal irradiation and chemotherapy with vincristine, cisplatin and cyclophosphamide have yielded 5-year overall survival rates of 70-80%, survivors are left with substantial neurocognitive impairments and treatment-related morbidity. 3, 4 MB has been classified into four principal subgroups using integrative genomic platforms.
1,2 Groups 1 and 2, referred to as WNT and sonic hedgehog (SHH), derive from dysregulation of these key developmental signaling pathways and Groups 3 and 4 are associated with the strong upregulation of c-MYC and N-MYC, respectively. 2, 5, 6 This subgroup stratification has generated four genetically distinct tumor identities, each with a characteristic clinical presentation and prognosis. 7 Group 3 tumors have shown the worst prognosis of all, emphasizing the need for the development of specialized therapeutics in this subgroup. 8 Recent reports suggest the presence of somatic copy-number aberrations and single-nucleotide variants that may present subgroup-specific therapeutic targets 9, 10 but to date, druggable targets for Group 3 MB have not been identified.
As in many other solid tumors 11 and hematopoietic cancers, 12 MB is characterized by the presence of cancer stem cells (CSCs) or MB stem cells (MBSCs) that possess the ability to sustain tumor growth. These cells were first isolated and characterized in 2004.
13
CD133 (Prom1), a pentaspan membrane glycoprotein, is a surface marker for MBSCs, although its functional role and signaling mechanisms are not well understood. 13, 14 Although some studies debate the role of CD133 in initiating tumors, 15 CD133-positive cells continue to retain a higher self-renewal capacity and multipotency. 16 The signal transducers and activators of transcription (STAT) family of transcription factors are present in the cytoplasm as inactive monomeric/dimeric forms and upon phosphorylation at key tyrosine residues (Tyr705), STATs translocate to the nucleus. This movement from cytoplasm to nucleus is due to reciprocal SH2 domain-pTyr binding interactions between two STAT molecules, leading to the formation of activated homodimers.
Group 3 MBSCs based on CD133 expression and showed upregulation of p-STAT3 and c-MYC in these cells compared with CD133-negative subpopulations. Thereafter using structure-based drug design, we developed novel STAT3 inhibitors that have the potential to cross the blood-brain-barrier, to treat MB in vivo. Although CD133 has been used primarily as a marker to identify CSCs in multiple human cancers including brain tumors, its functional role remains obscure and cannot be currently targeted using small molecules or inhibitors. Similarly, c-MYC is difficult to target due to our poor understanding of binding ligands and inability to specify context-dependent MYC-associated transcriptional gene expression across different cancers. 23 Our study presents a preclinical model applying STAT3 inhibitors to selectively target CD133 + MBSCs in Group 3 MB.
RESULTS
CD133 expression is upregulated in Group 3 MB cells CD133 is a marker used to enrich for human MBSCs, 6, 13, 14, 24 but its role and expression within subgroups remains unclear. To evaluate CD133 protein expression in MBSCs, we propagated in neural stem cell (NSC) media the MB Group 3 lines Med8A, D425, D458, CHLA-01R-MED, and measured CD133 expression by flow cytometery (Figure 1a ). It is noteworthy that D425 was derived from a primary cerebellar MB in a 6-year-old boy, whereas D458 was established from cerebrospinal metastasis after treatment failure from the same patient; thus D425 and D458 represent a matched primary and recurrent pair. 25 Interestingly, CD133 expression was significantly higher in recurrent MB lines (D458, CHLA-01R-MED) compared with primary (D425) lines. Phasecontrast pictures of MB cell lines are shown in Figure 1b .
When we probed multiple published MB transcriptional databases (Toronto, 5 Boston, 26 Amsterdam 27 and Memphis 28 ) for CD133 we found its expression was strongly associated with Group 3 MB (Figure 1c ). Data mined from the Boston database showed lower survival in CD133
high tumors (P = 0.01, hazard ratio = 2.4) compared with CD133 low tumors (Figure 1d ). To provide a functional context for the clinical utility of CD133 expression in Group 3 MB, we compared the proliferative potential between sorted CD133-positive and CD133-negative populations. When compared with CD133-negative cells, CD133-positive cells had significantly higher proliferation capacity in both primary and matched recurrent cells lines (D425 and D458, respectively, Figures 1e and f).
To further validate the functional role of CD133 in tumor formation, we xenografted mice intracranially with sorted CD133-positive or CD133-negative Group 3 MB cells. We found that CD133-positive cells formed very large tumors, whereas tumors obtained by xenograting CD133-negative cells were much smaller (Figure 1g ). Our data suggests that CD133 expression characterizes and may contribute to poor outcome in Group 3 MB through perpetuation of stem cell populations that drive tumorigenesis.
Activated STAT3 is enriched in CD133-high Group 3 MB Activated STAT3 signaling has been described in other CSC populations, including CD133-positive human colon cancer cell lines 29 and CD133 high hepatocellular carcinoma cell lines. 30 As high CD133 expression is a poor prognostic marker in many cancers 31 and we show that it correlates with poor patient outcome in Group 3 MB (Figure 1d ), we hypothesized that hyperactive signaling pathways in CD133-positive cells could be ideal therapeutic targets. In order to determine transcript levels of STAT3 among MB subgroups, we probed existing MB genomic platforms for its expression levels in different subgroups, as described previously for CD133. STAT3 expression levels were enriched in poor outcome non-Shh/Wnt subgroups, namely Group 3 and Group 4 MB (Figure 2a) . We then determined protein levels of CD133, STAT3 and p-STAT3 in Group 3 MB cells using Western blot, and again validated that recurrent lines, D458 and CHLA-01R-MED have comparatively higher expression of CD133 than D425 line (Figure 2b ). Although STAT3 expression is not significantly altered, activated STAT3 (p-STAT3) correlates with CD133 expression, and is especially elevated in recurrent Group 3 MB (Figure 2b ). To further probe the relationship between CD133 and activated STAT3 signaling, we ectopically overexpressed CD133 in the CD133 low Med8A Group 3 line. We validated overexpression of CD133 by RTPCR (Figure 2c ) and Flow analysis (Figure 2d ). Upon overexpression of CD133, MED8a cells showed a significant increase in p-STAT3 (Figure 2e ). Med8A cells overexpressing CD133 also showed increased proliferation capacity (Figure 2f ). Our data demonstrates that STAT3 signaling is activated in CD133+ Group 3 recurrent MB cells, and CD133 overexpression activates STAT3 to promote cell proliferation and growth of Group 3 MB. p-STAT3 contributes to tumorigenesis in Group 3 MB To investigate the role of STAT3 signaling in MB pathogenesis, we undertook lentiviral short-hairpin RNA-mediated knockdown of STAT3 in Group 3 patient-matched MB cell lines D425 (primary) and D458 (recurrent). Out of two vectors, shSTAT3-1 showed efficient knockdown in both cell lines D425 ( Figure 3a ) and D458 ( Figure 3b ) with prominent reduction in activated p-STAT3 levels. This knockdown correlated with reduction in proliferation capacity in both primary and recurrent MB (Figures 3c and d) . To further elucidate the role of STAT3 in tumor initiation/maintenance, we performed intracranial injections of STAT3-knockdown MB cells into NOD-SCID mice and found a significant reduction in tumor size when compared with control (shControl-transduced) tumors (Figures 3e-g ). Moreover, mice xenografted with shSTAT3-transduced cells treated survived longer than control mice (Figures 3h and i ). These data demonstrate the prominent role of STAT3 in regulating proliferation and tumorigenesis of Group 3 MBSCs.
Interplay between CD133, STAT3 and c-MYC may drive Group 3 MB c-MYC drives a regulatory network in embryonic stem cells that is also active in many cancers and drives poor outcomes. 32 c-MYC is further implicated in regulating Group 3 murine MBs that resemble their human counterpart. 6 CD133 and c-MYC have clearly been associated with relapse and poor prognosis in MB patients. 6 To explore how CD133, c-MYC and STAT3 may collectively regulate MBSCs, 30, 33, 34 we first probed MB transcriptome data to validate that c-MYC is highly enriched in Group 3 MB tumors (Supplementary Figure 1) . Although Group 3 MB lines used (D425, D458, Med8A and CHLA-01R-MED) showed varied mRNA expression levels of c-MYC (Figure 4a ), protein levels of c-MYC were higher in Group 3 recurrent lines D458 and CHLA-01R-MED (Figure 4b ). c-MYC is a known downstream target of STAT3 signaling in ovarian cancer and in glioblastoma stem cells, where STAT3 inhibitors have also reduced expression of stem cell-associated genes such as CD133. We show that p-STAT3 is upregulated in sorted CD133-positive populations from Group 3 MB lines, which also show enhanced c-MYC levels compared with CD133-negative populations (Figure 4c) . Moreover, as a proof of principle we looked at the levels of STAT3 and c-MYC after knockdown of STAT3 in both D425 and D458 cell lines and found significant downregulation of c-MYC after STAT3 knockdown (Supplementary Figure 2) . Expression levels of c-MYC are significantly higher in sorted CD133-positive cells compared with CD133-negative cells in D458 MB (Figure 4d ). Given the high levels of c-MYC in Group 3 MB, we performed proliferation assays using a cell permeable Figure 5) . This data shows that STAT3 inhibitor treatment at doses that would be tolerable in patients can decrease tumor burden of Group 3 MB xenografts, but with equal toxicity towards NSCs; implicating neurotoxicity as a potential side effect.
Systemic treatment with STAT3 inhibitors PG-S3-009 and PG-S3-010 reduces tumor formation in vivo As STAT3 signaling is active in MBSCs, we then investigated the role of STAT3 compounds in reducing tumor formation in our human-mouse xenograft model of Group 3 MB. We chose to Figure 7) . In order to evaluate the effect of the drug in vivo, NODSCID mice were intracranially xenografted with D458 cells and treated intraperitoneal with escalating doses of PG-S3-009 (DMSO, 5, 10 or 20 mg/kg) (Figure 7b) . Cohorts treated at 20 mg/kg with PG-S3-009 showed significant reduction in tumor burden compared with DMSO or lower-dose treated mice (Figures 7c and d) . However, no survival benefit was observed in treated mice compared with DMSO controls (Figure 7e ). Treated mice became anorexic and withdrew from feeding and activity, suggestive of treatment-induced neurotoxicity, although no toxicity was seen in liver, kidneys and lungs (data not shown). These data implicate the direct targeting of STAT3 by PG-S3-009 and subsequent downregulation of STAT3 leading to the reduction of the downstream target c-MYC in MBSCs (Supplementary Figure 8) .
DISCUSSION
The recent molecular classification of MB into four distinct subgroups implies that different subrgoup-specific therapeutic strategies need to be devised for individualized patient therapy.
This therapeutic roadmap may only be realized by elucidating the biological and genetic drivers of tumorigenesis in each subgroup, in order to discover tractable and druggable therapeutic targets. In this study, we link the high expression of CD133 with Group 3 MB and further correlate its expression with c-MYC, via STAT3. High c-Myc expression often reflects a classic Group 3 MB with metastasis at diagnosis, large cell histology and overall poor prognosis. 2 Novel mouse models have been developed using genetics to recapitulate human Group 3 MB that have the potential to be used for preclinical testing. 6, 36 Our observation of enrichment of CD133 in Group 3 MB is in accordance with the expression of this cell-surface marker in multiple CSC populations, which are thought to evade current chemoradiotherapy only to seed recurrent disease and drive patient relapse and poor outcome. 14 In light of the fact that Group 3 MB is the most aggressive among all subgroups, our understanding of the functional role of CD133 in Group 3 MB can provide a strategic platform to identify novel signaling inhibitors in CD133-positive cells for the effective management of these tumors. c-MYC expression can be regulated by numerous signaling pathways including the JAK/STAT, rendering STAT3 inhibitors attractive therapeutic options. As the Wnt subtype of + cells also showed increased protein expression of CD133 and p-STAT3 relative to GAPDH control as analyzed by western blotting. Bar represent expression levels relative to GAPDH of three technical replicates, mean ± s.d., two-way analysis of variance, P = 0.005. (e) D425 and D458 cells were treated with c-MYC inhibitor 10058-F4 and IC 50 curves were generated from inhibition of cell proliferation using Presto Blue assay with four technical replicates. IC 50 values are: D425: 189.148 μM and D458: 133.277 μM.
Targeting STAT3 in medulloblastoma stem cells N Garg et al MB (Group 1) also demonstrates elevated levels of c-Myc, STAT3 inhibitors could be considered as a therapeutic option for patients with this positive prognostic MB subtype. Activated STAT3 signaling has been shown to be essential for cell survival and tumorsphere-forming capacity in human colon cancer cell lines sorted for both ALDH (aldehyde dehydrogenase) and CD133 (ALDH + /CD133 + ). 29 Previous studies have shown that downregulation and inhibition of STAT3 signaling suppresses proliferation and induces apoptosis in human glioma cells [37] [38] [39] as well as various cancers. 40, 41 Xiao et al., have already shown that disruption of STAT3 signaling leads to inhibition of cell growth and apoptosis of medulloblastoma cells. 42 Using bioinformatics and microarray platforms, another study revealed STAT3/p-STAT3 signaling upregulated in CD133-positive MB cells compared with CD133-negative cells. 43 STAT3 has a key role in maintaining both tumor cells and its microenvironment, although little is known about both upstream and downstream regulators of JAK-STAT3 signaling. Despite advances in studying the role of STAT3 as an ideal target for CSC-driven tumors, 30, 33, 44 challenges have arisen in developing these drugs for clinical use. In general STAT3 inhibitors targeting the SH2 domain have suffered from limited clinical utility due to inclusion of polar groups designed to mimic SH2 domain binding Tyr705 residue that has resulted in metabolic instability and poor cell permeability. 42, 45 Non-phosphorylated small molecule inhibitors such as STA-201, 46 BP-1-102, 47 BP-5-87, 48 SH-4-54 44 and LY5 42 have, to a certain extent circumvented this problem. To enhance in vivo efficacy, SH-4-54 was optimized specifically to yield inhibitors with improved bioavailability. PG-S3-009 and PG-S3-010 were two of the most potent anti-cancer compounds to emerge from this program. These inhibitors have shown great promise in treating other treatment-refractory and aggressive cancers such as brain metastases. 49 Previous studies have suggested that c-MYC is a critical regulator of MB cell growth and proliferation. 32 The activation of 50 and its translocation to the nucleus permits activation of oncogenes and cell cycle regulatory genes such as c-MYC, cyclin-D1 and Cox-2, leading to cancer progression. 51 In another study, DNA microarray analysis in CD133-positive MB cells showed an upregulation of c-MYC. 52 Although both CD133 and c-MYC upregulation have clear implications in Group 3 MB pathogenesis, both are difficult to target owing to insufficient understanding of molecular mechanisms and their role in normal development and cancer. Currently there are no available drugs targeting CD133, and the c-MYC targeting compound 10058-F4 35 has a very high IC 50 value in MBSCs that may preclude clinical use. There are currently no clinically approved therapies for directly targeting c-MYC, as MYC is a pleiotropic transcription factor that controls expression of hundreds of genes. Moreover, 10058-F4 inhibits c-MYC/Max dimerization, 35 implying multiple off-target cellular activities through modulation of various transcription factors in other tissues and organs. Within the CD133/STAT3/c-MYC signaling axis, the only attractive target for drug development is STAT3. This concept prompted us to search for novel STAT3 inhibitors to treat Group 3 MB with the potential to translate into clinical settings.
STAT3 in MB
In this study, we demonstrate the enrichment of CD133 in Group 3 MBSCs and discover potential signaling mechanisms involving activated STAT3 (p-STAT3) and c-MYC in CD133-positive cells. Treatment with STAT3 dimerization inhibitor PG-S3-002 ex vivo significantly reduces tumor burden in mice. Our preclinical trial of another STAT3 inhibitor, PG-S3-009, showed reduced tumor burden in mice, but no significant survival benefit due to presumed neurotoxicity of the compound. However, if neurotoxicity could be mitigated with chemical modifications to the compound, these inhibitors show great promise in effectively treating recurrent MB (D458), an important result as Group 3 recurrence is currently treated with palliation alone. Our study describes the first preclinical evidence that novel STAT3 inhibitors cross the blood-brain-barrier and effectively treat recurrent Group 3 MB. were respectively downloaded and processed from GEO (GSE10327, GSE12992 and GSE7578) or http://www.stjuderesearch.org/site/data/ medulloblastoma 28 and normalized using RMA. 53 When available, clinical annotations for each tumor were also downloaded from these locations. CD133 signature for survival using Pomeroy database Survival analysis (for CD133) was completed in (R core team, Vienna, Austria), and Kaplan-Meier survival curves were drawn using GraphPad prism (GraphPad software, SanDiego, CA, USA).
MATERIALS AND METHODS
MB cell culture MB cell lines Med8A, D425 and D458 were cultured in DMEM high glucose (Life Technologies, Carlsbad, CA, USA; #11965-118) supplemented with 1% penicillin-streptomycin, 1% glutamine (Gibco) and 20% serum for Med8A, D425 and D548. CHLA-01R-MED (ATCC, Manassas, VA, USA; CRL-3034) was obtained the American Type Culture Collection (ATCC) and maintained in tumor sphere media as described previously. 54 Virus preparation and transduction Lentiviral vectors shSTAT3-1 and shSTAT3-2 expressing short-hairpin RNAtargeting human STAT3 (target sequence: 5′-TGCATGTCTCCTTGACTCT-3′, 5′-TACCTAAGGCCATGAACTT-3′, respectively) and control scrambled shorthairpin RNA vector were purchased from Thermo Scientific (Waltham, MA, USA). CD133 overexpression vector was purchased from Genecopoeia (Rockville, MD, USA). Replication-incompetent lentivirus was produced. Briefly, after co-transfection of expression vector and packaging plasmids, viral supernatants were harvested 48 h after transfection. Thereafter, supernatant was filtered through a 0.45 μm cellulose acetate filter and precipitated with PEGit (System biosciences, Palo Alto, CA, USA). After precipitation, viral pellets were re-suspended in 1.0 ml of DMEM F-12 media and stored at − 80°C until further used. To generate stable shSTAT3 lines, MB cells were transduced with lentivirus prepared as stated above. After 48 h of transduction, cells were grown in media containing 1 μg/ml of puromycin to generate stable cell lines.
Western immunoblotting
Proteins from cell lysates were extracted and quantified as described previously. 24 Briefly, 20 μg of total protein was run using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and proteins were then transferred to polyvinylidene fluoride membrane. Blots were probed for the following antibodies: anti-CD133 (1:500; Millipore, Etobicoke, ON, Canada; #MAB4399 clone 17A6.1), anti-c-MYC (1:1000; Cell signaling, Danvers, MA, USA; #5605), anti-STAT3 (1:1000; Cell Signaling #9139), antiphospho STAT3 (1:1000; Cell Signaling; #4113), anti-GAPDH (1:40,000; Abcam, Toronto, ON, Canada; #ab8245). Secondary antibodies were conjugated with horseradish peroxidase and procured from Bio-Rad (Mississauga, ON, Canada; Goat anti-mouse IgG) or Sigma (Oakville, ON, Canada; goat anti-rabbit IgG) and chemidoc was used for visualization of protein bands.
Cell proliferation assay
Using 96-well plates, single cells were plated at a density of 1000 cells/200μl per well in quadruplicate for each sample and incubated for 4 days. After 4 days, 20μl of Presto Blue (Life technologies), a cell viability indicator, were added to each well~4 h prior to the readout time point. Fluorescence was measured using a FLUOstar Omega Fluorescence 556 Microplate reader (BMG LABTECH) at excitation and emission wavelengths of 540-570 nm and 580-610 nm, respectively. Readings were analyzed using MARS data analysis software (Guelph, ON, Canada).
Cell sorting and analysis using flow cytometry Tumorspheres/cell aggregates were dissociated using liberase (Roche, Laval, QC, Canada) and cells at a concentration of 1 million single cells/ml in phosphate-buffered saline+2 mM EDTA were stained with APCconjugated anti-CD133 or a matched isotype control (Miltenyi, Auburn, CA, USA). The MoFlo XDP Cell Sorter was used to analyze/sort samples and Kaluza software (Beckman Coulter, Mississauga, ON, Canada) was used for analysis. Mouse IgG CompBeads (BD, San Jose, CA, USA) were used for compensation and viability dye 7-AAD dye (1:10; Beckman Coulter) was added in samples to exclude dead cells. Purity check for CD133 expression levels after sorting was also performed.
Quantitative real-time-polymerase chain Norgen Total RNA isolation kit was used for RNA extraction. RNA was quantified using NanoDrop Spectrophotometer ND-1000 (Thermoscientific, Wilmington, DE, USA). Using 1 μg RNA, complementary DNA was synthesized using qScript cDNA Super Mix (Quanta Biosciences, Beverly, MA, USA) and a C1000 Thermo Cycler (Bio-Rad, Mississauga, ON, Canada) with the following cycle parameters: 4 min at 25°C, 30 min at 42°C, 5 min at 85°C, hold at 4°C. qRT-PCR was performed using Perfecta SybrGreen (Quanta Biosciences) and an 4CFX96 instrument (Bio-Rad) as described previously. 55 Gene expression was quantified by using CFX Manager 3.0 (Bio Rad) software and expression levels were normalized to GAPDH/Actin expression. Primers are listed in Supplementary Table 1 .
Screening of MBSCs with STAT3 inhibitors
Dr Patrick Gunning provided a library of proprietary direct-binding STAT3 inhibitors. Cell proliferation in MBSCs (grown in DMEM supplemented with 20% fetal bovine serum) was determined by plotting percentage cell viability versus log dilutions of the inhibitors, giving IC 50 . To assess tumor inhibition in mice, compound PG-S3-002 was chosen for ex vivo treatment and modification of compound PG-S3-002 resulted in synthesis of compound PG-S3-009, which has increased bioavailability and was used for in vivo treatment. See Supplementary Figure 8 for details about PG-S3-009.
In vivo intracranial injections of MB stem cells and H&E staining of xenograft tumors
The McMaster University Animal Research Ethics Board (AREB) approved all experimental procedures and intracranial injections were performed as described previously. 13 Briefly, live cells (numbers mentioned in figure legends) re-suspended in 10 μl of phosphate-buffered saline were injected into the frontal lobe of NOD-SCID mice (both males and females of 8-10 weeks of age). Mice injected with CD133 sorted cells (positive or negative) were killed when the CD133-positive group reached end point. Treated mice (with either shSTAT3 or ex vivo STAT3 inhibitor or in vivo STAT3 inhibitor) were killed when control Group/untreated mice reached end point as shown by signs of illness, for tumor size quantification. Mice were randomized into control or treatment groups. Group allocation was not blinded. For survival studies, treated or control mice were killed when they reached end point. The treatment did not induce adverse weight loss that would be contraindicated by our animal utilization protocol (AUP) endpoints policy.
Mouse brains were harvested, formalin-fixed and thereafter brain sections were paraffin-embedded and also stained for hematoxylin and eosin (Cell Signaling). Aperio Slide Scanner (Leica Biosystems, Concord, ON, Canada) was used to scan images and images were analyzed using ImageScope v11.1.2.760 software (Aperio, Concord, ON, Canada). Survival curves were plotted using Graphpad Prism 5 (SanDiego, CA, USA).
Statistical analysis
Technical/experimental replicates from at least three samples were compiled for each experiment, unless otherwise stated in figure legends. Respective data represent mean ± s.d. with n values listed in figure legends. Student's t-test analyses and two-way analysis of variance were performed using GraphPad Prism 5. Po 0.05 was considered significant. For in silico analyses, statistical tests were complied and completed in R.
